Medexus Pharmaceuticals Statistics

Total Valuation

MEDXF has a market cap or net worth of 69.05 million. The enterprise value is 82.92 million.

Market Cap	69.05M
Enterprise Value	82.92M

Important Dates

The last earnings date was Monday, June 23, 2025.

Earnings Date	Jun 23, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	32.26M
Shares Outstanding	n/a
Shares Change (YoY)	+18.76%
Shares Change (QoQ)	+19.97%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	29.87M

Valuation Ratios

The trailing PE ratio is 30.73 and the forward PE ratio is 12.17.

PE Ratio	30.73
Forward PE	12.17
PS Ratio	0.64
PB Ratio	1.32
P/TBV Ratio	n/a
P/FCF Ratio	2.90
P/OCF Ratio	2.87
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 4.13, with an EV/FCF ratio of 3.48.

EV / Earnings	36.90
EV / Sales	0.73
EV / EBITDA	4.13
EV / EBIT	6.62
EV / FCF	3.48

Financial Position

The company has a current ratio of 0.83, with a Debt / Equity ratio of 0.71.

Current Ratio	0.83
Quick Ratio	0.38
Debt / Equity	0.71
Debt / EBITDA	1.95
Debt / FCF	1.56
Interest Coverage	1.45

Financial Efficiency

Return on equity (ROE) is 5.45% and return on invested capital (ROIC) is 8.79%.

Return on Equity (ROE)	5.45%
Return on Assets (ROA)	4.55%
Return on Invested Capital (ROIC)	8.79%
Return on Capital Employed (ROCE)	16.00%
Revenue Per Employee	1.19M
Profits Per Employee	24,692
Employee Count	91
Asset Turnover	0.66
Inventory Turnover	1.17

Taxes

Income Tax	-807,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +25.89% in the last 52 weeks. The beta is 2.04, so MEDXF's price volatility has been higher than the market average.

Beta (5Y)	2.04
52-Week Price Change	+25.89%
50-Day Moving Average	2.13
200-Day Moving Average	2.04
Relative Strength Index (RSI)	49.61
Average Volume (20 Days)	6,124

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, MEDXF had revenue of 108.33 million and earned 2.25 million in profits. Earnings per share was 0.08.

Revenue	108.33M
Gross Profit	63.51M
Operating Income	11.92M
Pretax Income	1.44M
Net Income	2.25M
EBITDA	18.94M
EBIT	11.92M
Earnings Per Share (EPS)	0.08

Full Income Statement

Balance Sheet

The company has 23.97 million in cash and 37.18 million in debt, giving a net cash position of -13.21 million.

Cash & Cash Equivalents	23.97M
Total Debt	37.18M
Net Cash	-13.21M
Net Cash Per Share	n/a
Equity (Book Value)	52.14M
Book Value Per Share	1.62
Working Capital	-16.74M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 24.03 million and capital expenditures -183,000, giving a free cash flow of 23.85 million.

Operating Cash Flow	24.03M
Capital Expenditures	-183,000
Free Cash Flow	23.85M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 58.62%, with operating and profit margins of 11.00% and 2.07%.

Gross Margin	58.62%
Operating Margin	11.00%
Pretax Margin	1.33%
Profit Margin	2.07%
EBITDA Margin	17.48%
EBIT Margin	11.00%
FCF Margin	22.02%

Dividends & Yields

MEDXF does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18.76%
Shareholder Yield	n/a
Earnings Yield	3.25%
FCF Yield	34.54%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

The last stock split was on December 19, 2018. It was a reverse split with a ratio of 0.0666666.

Last Split Date	Dec 19, 2018
Split Type	Reverse
Split Ratio	0.0666666

Scores

MEDXF has an Altman Z-Score of 0.47 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.47
Piotroski F-Score	5